Ottobock SE & Co. KGaA
Research Ottobock SE & Co. KGaA (OBCK) on Bullrun: valuation model: 2.1% undervalued, market cap EUR 3.28B, P/E 25.3, dividend yield 1.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOBCK
- ExchangeXETRA
- CountryGermany
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyEUR
- Valuation signal2.1% undervalued
- Market capEUR 3.28B
- P/E25.3
- Dividend yield1.8%
- Financial periodQ1 2026
- RevenueEUR 396.00M
- Net incomeEUR 19.00M
- Free cash flowEUR 41.10M
- Gross margin52.1%
Valuation Snapshot
Bullrun's latest valuation model marks Ottobock SE & Co. KGaA as 2.1% undervalued; latest market cap is EUR 3.28B; P/E is 25.3; dividend yield is 1.8%.
Peer valuation comparison
Latest P/E is 25.27x versus a Healthcare sector median of 24.6x (2.7% above).
Latest dividend yield is 1.81% versus a Healthcare sector median of 1.84%.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 1.68B | EUR 90.20M | EUR 224.50M | 52.8% | 1.44 | EUR 90.40M | EUR 1.12B | EUR 397.50M |
| FY2024 | EUR 1.61B | EUR 30.20M | EUR 173.10M | 50.6% | 0.47 | EUR 76.70M | EUR 1.27B | EUR 249.50M |
| FY2023 | EUR 1.50B | EUR 48.96M | EUR 103.22M | 46.5% | 0.77 | EUR 65.27M | EUR 1.26B | EUR 229.41M |
| FY2022 | EUR 1.33B | EUR 76.44M | -EUR 16.31M | 44.7% | 13.96 | EUR 79.15M | EUR 1.26B | EUR 237.11M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-08 | EUR 3.28B | 25.3 | 1.9% | 0.97 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.97 EUR, yield 1.8%.
About Ottobock SE & Co. KGaA
Ottobock SE & Co. KGaA develops, produces, and distributes medical technology products and components for the people with disabilities in the fields of prosthetics, orthotics, human mobility, and industrial exoskeletons in Europe, the Middle East, Africa, North and South America, and the Asia Pacific. The company is involved in identification, development, manufacturing, sales, and marketing of prosthetics, neuro-orthotics, and digital solutions; prostheses for the upper and lower extremities;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Ottobock SE & Co. KGaA overvalued or undervalued?
Bullrun's valuation model currently marks Ottobock SE & Co. KGaA as 2.1% undervalued.
What is Ottobock SE & Co. KGaA's market cap?
Ottobock SE & Co. KGaA's market capitalization is EUR 3.28B.
What is Ottobock SE & Co. KGaA's P/E ratio?
Ottobock SE & Co. KGaA's price-to-earnings (P/E) ratio is 25.3.
Does Ottobock SE & Co. KGaA pay a dividend?
Ottobock SE & Co. KGaA has a dividend yield of 1.8%.
What does Ottobock SE & Co. KGaA do?
Ottobock SE & Co. KGaA develops, produces, and distributes medical technology products and components for the people with disabilities in the fields of prosthetics, orthotics, human mobility, and industrial exoskeletons in Europe, the Middle East, Africa, North and South America, and the Asia Pacific.